Ali Alkhaibary1, Ali H Alassiri2, Fahd AlSufiani3, Mohammed A Alharbi3. 1. College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. Electronic address: AlkhaibaryA@hotmail.com. 2. King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. 3. Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Abstract
OBJECTIVE/ BACKGROUND: Glioblastoma (GB) is the most common primary malignant brain tumor in adults. Ki-67 is a nonhistone nuclear protein that is expressed by cells entering the mitotic cycle and is associated with the transcription of ribosomal RNA (rRNA). In gliomas, the extent of expression of Ki-67 is roughly proportional to the histologic grade. Over the years, association studies were conducted trying to link the poor outcome in different types of malignant tumors to the Ki-67 proliferative index. This study is designed to investigate the relationship between the proliferation marker, Ki-67, and the overall survival amongst glioblastoma patients diagnosed between 2006 and 2012 at a single institution in Riyadh, Saudi Arabia. METHODS: This is a retrospective cohort study which investigated the status of Ki-67 labeling index in glioblastoma patients diagnosed at King Abdulaziz Medical City, Riyadh, Saudi Arabia, between 2006 and 2012. The Kaplan-Meier survival analysis was used to assess the overall survival (OS) and the Mantel-Cox log-rank test was used to compare the survival curves. Multivariate analysis using Cox proportional-hazards model was used to investigate other factors that might influence the overall survival. RESULTS: A total of 44 glioblastoma patients were included in the study. The median age at diagnosis was 56 (1-91) years. The 12-month survival rate for all glioblastoma patients was 48%. The median survival for patients with Ki-67 labeling index of ≤27%, and >27% was 11 months and 14 months, respectively. CONCLUSION: The difference between the survival curves of patients with Ki-67 labeling index of ≤27%, and Ki-67 of >27% was statistically insignificant (p = .130). Therefore, Ki-67 labeling index alone cannot predict survival in glioblastoma patients.
OBJECTIVE/ BACKGROUND:Glioblastoma (GB) is the most common primary malignant brain tumor in adults. Ki-67 is a nonhistone nuclear protein that is expressed by cells entering the mitotic cycle and is associated with the transcription of ribosomal RNA (rRNA). In gliomas, the extent of expression of Ki-67 is roughly proportional to the histologic grade. Over the years, association studies were conducted trying to link the poor outcome in different types of malignant tumors to the Ki-67 proliferative index. This study is designed to investigate the relationship between the proliferation marker, Ki-67, and the overall survival amongst glioblastomapatients diagnosed between 2006 and 2012 at a single institution in Riyadh, Saudi Arabia. METHODS: This is a retrospective cohort study which investigated the status of Ki-67 labeling index in glioblastomapatients diagnosed at King Abdulaziz Medical City, Riyadh, Saudi Arabia, between 2006 and 2012. The Kaplan-Meier survival analysis was used to assess the overall survival (OS) and the Mantel-Cox log-rank test was used to compare the survival curves. Multivariate analysis using Cox proportional-hazards model was used to investigate other factors that might influence the overall survival. RESULTS: A total of 44 glioblastomapatients were included in the study. The median age at diagnosis was 56 (1-91) years. The 12-month survival rate for all glioblastomapatients was 48%. The median survival for patients with Ki-67 labeling index of ≤27%, and >27% was 11 months and 14 months, respectively. CONCLUSION: The difference between the survival curves of patients with Ki-67 labeling index of ≤27%, and Ki-67 of >27% was statistically insignificant (p = .130). Therefore, Ki-67 labeling index alone cannot predict survival in glioblastomapatients.
Authors: Mrunal Vitthal Wanjale; Vishnu Sunil Jaikumar; K C Sivakumar; Riya Ann Paul; Jackson James; G S Vinod Kumar Journal: Int J Nanomedicine Date: 2022-05-16
Authors: Ricardo Caramanti; Raysa M Aprígio; Carlos E D Aglio Rocha; Dionei F Morais; Mário J Góes; Feres Chaddad-Neto; Waldir A Tognola Journal: Cureus Date: 2022-04-18
Authors: Leonardo Jose Monteiro de Macedo Filho; Esther Grangeiro Barreto; Paulo Levi Bezerra Martins; Euler Nicolau Sauaia Filho; Gunter Gerson; Lucas Alverne Freitas de Albuquerque Journal: Surg Neurol Int Date: 2020-11-06
Authors: Michael Naidoo; Leanne Jones; Benjamin Conboy; Wael Hamarneh; Darwin D'Souza; Karen Anthony; Lee R Machado Journal: Sci Rep Date: 2022-02-25 Impact factor: 4.379
Authors: Charlotte Bouckaert; Charlotte Germonpré; Jeroen Verhoeven; Seon-Ah Chong; Lucas Jacquin; Georges Mairet-Coello; Véronique Marie André; Karine Leclercq; Christian Vanhove; Filip De Vos; Caroline Van den Broecke; Ingeborg Goethals; Benedicte Descamps; Sam Donche; Evelien Carrette; Wytse Wadman; Paul Boon; Kristl Vonck; Robrecht Raedt Journal: Int J Mol Sci Date: 2020-09-23 Impact factor: 5.923